Enzo Biochem (ENZ) Reports Q2 EPS of $0.09, CEO to Step Down
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
March 15, 2021 4:05 PM EDTTotal second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemicSecond quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-yearAchieved adjusted EBITDA at $4.3 million for the quarter with increases in sequential and YOY profitabilityEPS of $0.05 for the quarter vs. EPS loss of ($0.16) in Q2 2020Dr. Elazar Rabbani, Founder and CEO, to step down as CEO and transition... More
